Federal Project Grant Award Summary

The University of British Columbia received a $700,000 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) with an award date of May 1, 2026, and performance period through April 30, 2030. The research project, titled "Do Epithelial Mutations and Exhausted T Cells Conspire to Create a Tumor Prone Niche for Endometriosis Associated Ovarian Cancer Development," delivers hypothesis-driven biomedical research services investigating the mechanisms underlying endometriosis-associated ovarian cancer. The research will be conducted at the university's facilities in Ottawa, Ontario, Canada, with the objective of advancing understanding of cancer development through examination of cellular and immunological factors.

As a major research institution with established federal contracting experience, UBC will provide translational research services including experimental investigation, physiological analysis, and potential therapeutic discovery related to cancer immunotherapy and oncology. This award aligns with the Military Medical Research and Development program's focus on innovative medical solutions addressing critical health challenges through advanced biomedical research conducted at eligible extramural institutions. The four-year performance period is consistent with typical timelines for this DHA program, which typically supports awards ranging from $100,000 to $20 million depending on project scope and funding priorities.